BioMarin to Participate in Four Upcoming Investor Conferences in March 2026

The biotech company will present at multiple healthcare investor events across the country.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

BioMarin Pharmaceutical Inc., a leading global rare disease biotechnology company, today announced that its management team will participate in four upcoming investor conferences in March 2026. The conferences include the TD Cowen 46th Annual Health Care Conference, Leerink 2026 Global Healthcare Conference, Jefferies 2026 Biotech on the Beach Summit, and Barclays 28th Annual Global Healthcare Conference.

Why it matters

Participation in these high-profile investor conferences allows BioMarin to showcase its pipeline of innovative rare disease therapies and connect with the investment community. As a public company, these events are important for maintaining transparency and building confidence among shareholders.

The details

At the conferences, BioMarin executives including President & CEO Alexander Hardy, CFO Brian Mueller, and Chief Commercial Officer Cristin Hubbard will deliver presentations, participate in fireside chats, and host one-on-one investor meetings. The company's presentations will be webcast live and available for replay on BioMarin's investor relations website.

  • The TD Cowen 46th Annual Health Care Conference will take place on Wednesday, March 4, 2026.
  • The Leerink 2026 Global Healthcare Conference is scheduled for Monday, March 9, 2026.
  • The Jefferies 2026 Biotech on the Beach Summit will be held on Tuesday, March 10, 2026.
  • The Barclays 28th Annual Global Healthcare Conference is set for Wednesday, March 11, 2026.

The players

BioMarin Pharmaceutical Inc.

A leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997 and headquartered in San Rafael, California, the company has a proven track record of innovation with multiple commercial therapies and a strong clinical and preclinical pipeline.

Alexander Hardy

President and Chief Executive Officer of BioMarin Pharmaceutical Inc.

Brian Mueller

Executive Vice President and Chief Financial Officer of BioMarin Pharmaceutical Inc.

Cristin Hubbard

Executive Vice President and Chief Commercial Officer of BioMarin Pharmaceutical Inc.

Got photos? Submit your photos here. ›

The takeaway

BioMarin's participation in these high-profile investor conferences underscores the company's commitment to transparency and engagement with the investment community as it continues to advance its pipeline of innovative rare disease therapies.